The Asia Pacific Real World Evidence Solutions Market would witness market growth of 9.0% CAGR during the forecast period (2022-2028).
The major pharmaceutical companies use a clinico-genomic database containing tumor sequencing data for cancer discovery investigations and the development of targeted drugs. As a result, businesses are able to perform a modest number of clinical trials for the uncommon biomarker-defined group while also expanding their range of indications. Thus, it shows that the market for real-world evidence solutions will rise in the coming years.
RWE can add patient-generated data, like biometric data or patient-reported outcomes (PROs), that is simpler to obtain between doctor visits to traditional outcome measurements during clinical studies. RWE is able to monitor quality and result metrics across organizations. For example, RWE can notify administrators of the benchmarking performance of their physicians and the performance of their overall health system compared to others.
This information can improve quality-based reimbursement schemes that honor good results and can assist payers and consumers in having more informed coverage discussions. Clinical registries, like the patient, product, and claims registries, are rich sources of RWD addition to that. They are essential resources for producing RWE and utilizing it to facilitate post-market investigation and surveillance.
Using RWE for regulatory & reimbursement decision-making is a journey that governments and regulators around the Asia Pacific are at various levels of. To show RWE's advantages and capabilities, some have already released formal advice and are moving on with pilot projects. Others are still in the initial phases of those approaches. Due to China's growing need for empirical data to support healthcare decisions, many new data sources have developed. Health economics, epidemiology, and outcomes research have not comprehensively assessed the real-world healthcare data sources that are currently available. Thus, the increased utilization of real world evidence in healthcare sector is driving the growth of Asia Pacific real world evidence solutions market.
The China market dominated the Asia Pacific Real World Evidence Solutions Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $4,657.7 million by 2028.The Japan market is estimated to grow a CAGR of 8.4% during (2022 - 2028). Additionally, The India market would experience a CAGR of 9.7% during (2022 - 2028).
Based on Component, the market is segmented into Services and Data Set. Based on Therapeutic Area, the market is segmented into Oncology, Cardiology, Neurology, Diabetes, Respiratory and Others. Based on End-user, the market is segmented into Healthcare Companies, Healthcare Payers, Healthcare Providers and Others. Based on Application, the market is segmented into Drug Development & Approvals, Medical Device Development & Approvals, Reimbursement/Coverage & Regulatory Decision Making and Post Market Safety & Adverse Events Monitoring. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include IBM Corporation, Oracle Corporation, Medpace Holdings, Inc., IQVIA Holdings, Inc., ICON plc, PerkinElmer, Inc., Parexel International Corporation (Phoenix Parentco, Inc.), PPD, Inc. (Thermo Fisher Scientific, Inc.), UnitedHealth Group, Inc. (Optum, Inc.), and Syneos Health, Inc.
The major pharmaceutical companies use a clinico-genomic database containing tumor sequencing data for cancer discovery investigations and the development of targeted drugs. As a result, businesses are able to perform a modest number of clinical trials for the uncommon biomarker-defined group while also expanding their range of indications. Thus, it shows that the market for real-world evidence solutions will rise in the coming years.
RWE can add patient-generated data, like biometric data or patient-reported outcomes (PROs), that is simpler to obtain between doctor visits to traditional outcome measurements during clinical studies. RWE is able to monitor quality and result metrics across organizations. For example, RWE can notify administrators of the benchmarking performance of their physicians and the performance of their overall health system compared to others.
This information can improve quality-based reimbursement schemes that honor good results and can assist payers and consumers in having more informed coverage discussions. Clinical registries, like the patient, product, and claims registries, are rich sources of RWD addition to that. They are essential resources for producing RWE and utilizing it to facilitate post-market investigation and surveillance.
Using RWE for regulatory & reimbursement decision-making is a journey that governments and regulators around the Asia Pacific are at various levels of. To show RWE's advantages and capabilities, some have already released formal advice and are moving on with pilot projects. Others are still in the initial phases of those approaches. Due to China's growing need for empirical data to support healthcare decisions, many new data sources have developed. Health economics, epidemiology, and outcomes research have not comprehensively assessed the real-world healthcare data sources that are currently available. Thus, the increased utilization of real world evidence in healthcare sector is driving the growth of Asia Pacific real world evidence solutions market.
The China market dominated the Asia Pacific Real World Evidence Solutions Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $4,657.7 million by 2028.The Japan market is estimated to grow a CAGR of 8.4% during (2022 - 2028). Additionally, The India market would experience a CAGR of 9.7% during (2022 - 2028).
Based on Component, the market is segmented into Services and Data Set. Based on Therapeutic Area, the market is segmented into Oncology, Cardiology, Neurology, Diabetes, Respiratory and Others. Based on End-user, the market is segmented into Healthcare Companies, Healthcare Payers, Healthcare Providers and Others. Based on Application, the market is segmented into Drug Development & Approvals, Medical Device Development & Approvals, Reimbursement/Coverage & Regulatory Decision Making and Post Market Safety & Adverse Events Monitoring. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include IBM Corporation, Oracle Corporation, Medpace Holdings, Inc., IQVIA Holdings, Inc., ICON plc, PerkinElmer, Inc., Parexel International Corporation (Phoenix Parentco, Inc.), PPD, Inc. (Thermo Fisher Scientific, Inc.), UnitedHealth Group, Inc. (Optum, Inc.), and Syneos Health, Inc.
Scope of the Study
Market Segments Covered in the Report:
By Component
- Services
- Data Set
By Therapeutic Area
- Oncology
- Cardiology
- Neurology
- Diabetes
- Respiratory
- Others
By End-user
- Healthcare Companies
- Healthcare Payers
- Healthcare Providers
- Others
By Application
- Drug Development & Approvals
- Medical Device Development & Approvals
- Reimbursement/Coverage & Regulatory Decision Making
- Post Market Safety & Adverse Events Monitoring
By Country
- China
- Japan
- India
- South Korea
- Singapore
- Malaysia
- Rest of Asia Pacific
Key Market Players
List of Companies Profiled in the Report:
- IBM Corporation
- Oracle Corporation
- Medpace Holdings, Inc
- IQVIA Holdings, Inc
- ICON plc
- PerkinElmer, Inc
- Parexel International Corporation (Phoenix Parentco, Inc.)
- PPD, Inc. (Thermo Fisher Scientific, Inc.)
- UnitedHealth Group, Inc. (Optum, Inc.)
- Syneos Health, Inc
Unique Offerings
- Exhaustive coverage
- The highest number of Market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Asia Pacific Real World Evidence Solutions Market, by Component
1.4.2 Asia Pacific Real World Evidence Solutions Market, by Therapeutic Area
1.4.3 Asia Pacific Real World Evidence Solutions Market, by End-user
1.4.4 Asia Pacific Real World Evidence Solutions Market, by Application
1.4.5 Asia Pacific Real World Evidence Solutions Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market Scenario and Composition
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Strategies Deployed in Real World Evidence Solutions Market
Chapter 4. Asia Pacific Real World Evidence Solutions Market by Component
4.1 Asia Pacific Services Market by Country
4.2 Asia Pacific Data Set Market by Country
Chapter 5. Asia Pacific Real World Evidence Solutions Market by Therapeutic Area
5.1 Asia Pacific Oncology Market by Country
5.2 Asia Pacific Cardiology Market by Country
5.3 Asia Pacific Neurology Market by Country
5.4 Asia Pacific Diabetes Market by Country
5.5 Asia Pacific Respiratory Market by Country
5.6 Asia Pacific Others Market by Country
Chapter 6. Asia Pacific Real World Evidence Solutions Market by End-user
6.1 Asia Pacific Healthcare Companies Market by Country
6.2 Asia Pacific Healthcare Payers Market by Country
6.3 Asia Pacific Healthcare Providers Market by Country
6.4 Asia Pacific Others Market by Country
Chapter 7. Asia Pacific Real World Evidence Solutions Market by Application
7.1 Asia Pacific Drug Development & Approvals Market by Country
7.2 Asia Pacific Medical Device Development & Approvals Market by Country
7.3 Asia Pacific Reimbursement/Coverage & Regulatory Decision Making Market by Country
7.4 Asia Pacific Post Market Safety & Adverse Events Monitoring Market by Country
Chapter 8. Asia Pacific Real World Evidence Solutions Market by Country
8.1 China Real World Evidence Solutions Market
8.1.1 China Real World Evidence Solutions Market by Component
8.1.2 China Real World Evidence Solutions Market by Therapeutic Area
8.1.3 China Real World Evidence Solutions Market by End-user
8.1.4 China Real World Evidence Solutions Market by Application
8.2 Japan Real World Evidence Solutions Market
8.2.1 Japan Real World Evidence Solutions Market by Component
8.2.2 Japan Real World Evidence Solutions Market by Therapeutic Area
8.2.3 Japan Real World Evidence Solutions Market by End-user
8.2.4 Japan Real World Evidence Solutions Market by Application
8.3 India Real World Evidence Solutions Market
8.3.1 India Real World Evidence Solutions Market by Component
8.3.2 India Real World Evidence Solutions Market by Therapeutic Area
8.3.3 India Real World Evidence Solutions Market by End-user
8.3.4 India Real World Evidence Solutions Market by Application
8.4 South Korea Real World Evidence Solutions Market
8.4.1 South Korea Real World Evidence Solutions Market by Component
8.4.2 South Korea Real World Evidence Solutions Market by Therapeutic Area
8.4.3 South Korea Real World Evidence Solutions Market by End-user
8.4.4 South Korea Real World Evidence Solutions Market by Application
8.5 Singapore Real World Evidence Solutions Market
8.5.1 Singapore Real World Evidence Solutions Market by Component
8.5.2 Singapore Real World Evidence Solutions Market by Therapeutic Area
8.5.3 Singapore Real World Evidence Solutions Market by End-user
8.5.4 Singapore Real World Evidence Solutions Market by Application
8.6 Malaysia Real World Evidence Solutions Market
8.6.1 Malaysia Real World Evidence Solutions Market by Component
8.6.2 Malaysia Real World Evidence Solutions Market by Therapeutic Area
8.6.3 Malaysia Real World Evidence Solutions Market by End-user
8.6.4 Malaysia Real World Evidence Solutions Market by Application
8.7 Rest of Asia Pacific Real World Evidence Solutions Market
8.7.1 Rest of Asia Pacific Real World Evidence Solutions Market by Component
8.7.2 Rest of Asia Pacific Real World Evidence Solutions Market by Therapeutic Area
8.7.3 Rest of Asia Pacific Real World Evidence Solutions Market by End-user
8.7.4 Rest of Asia Pacific Real World Evidence Solutions Market by Application
Chapter 9. Company Profiles
9.1 IBM Corporation
9.1.1 Company Overview
9.1.2 Financial Analysis
9.1.3 Regional & Segmental Analysis
9.1.4 Research & Development Expenses
9.1.5 Recent strategies and developments:
9.1.5.1 Acquisition and Mergers:
9.1.6 SWOT Analysis
9.2 Oracle Corporation
9.2.1 Company Overview
9.2.2 Financial Analysis
9.2.3 Segmental and Regional Analysis
9.2.4 Research & Development Expense
9.2.5 SWOT Analysis
9.3 PPD, Inc. (Thermo Fisher Scientific, Inc.)
9.3.1 Company Overview
9.3.2 Financial Analysis
9.3.3 Segmental and Regional Analysis
9.3.4 Research & Development Expense
9.3.5 SWOT Analysis
9.4 UnitedHealth Group, Inc. (Optum, Inc.)
9.4.1 Company Overview
9.4.2 Financial Analysis
9.4.3 Segmental Analysis
9.5 Syneos Health, Inc.
9.5.1 Company Overview
9.5.2 Financial Analysis
9.5.3 Segmental and Regional Analysis
9.5.4 Recent strategies and developments:
9.5.4.1 Acquisition and Mergers:
9.6 IQVIA Holdings, Inc.
9.6.1 Company Overview
9.6.2 Financial Analysis
9.6.3 Segmental and Regional Analysis
9.6.4 Recent strategies and developments:
9.6.4.1 Partnerships, Collaborations, and Agreements:
9.6.4.2 Acquisition and Mergers:
9.7 Medpace Holdings, Inc.
9.7.1 Company Overview
9.7.2 Financial Analysis
9.8 ICON plc
9.8.1 Company Overview
9.8.2 Financial Analysis
9.8.3 Regional Analysis
9.8.4 Recent strategies and developments:
9.8.4.1 Acquisition and Mergers:
9.9 PerkinElmer, Inc.
9.9.1 Company Overview
9.9.2 Financial Analysis
9.9.3 Segmental and Regional Analysis
9.9.4 Research & Development Expense
9.9.5 Recent strategies and developments:
9.9.5.1 Product Launches and Product Expansions:
9.10. Parexel International Corporation (Phoenix Parentco, Inc.)
9.10.1 Company Overview
9.10.2 Recent strategies and developments:
9.10.2.1 Partnerships, Collaborations, and Agreements:
Companies Mentioned
- IBM Corporation
- Oracle Corporation
- Medpace Holdings, Inc.
- IQVIA Holdings, Inc.
- ICON plc
- PerkinElmer, Inc.
- Parexel International Corporation (Phoenix Parentco, Inc.)
- PPD, Inc. (Thermo Fisher Scientific, Inc.)
- UnitedHealth Group, Inc. (Optum, Inc.)
- Syneos Health, Inc.
Methodology
LOADING...
